scholarly journals HPV co-testing as cervical screening test, Experience of Alweiya early detection cervical clinic: one-year Analysis

2020 ◽  
Vol 6 (5) ◽  
Author(s):  
Zainab J Al-Jobawi ◽  
Besmah M. Ali ◽  
Asan A Al-Niyazee ◽  
Mustafa H Ibraheem

Objectives: The high-risk Human papilloma virus test with conventional cytology (HPVco-test) was firstly introduced in our institute at May 2019 so we aimed to estimate the prevalence of abnormal cytology and positive high-risk human papillomavirus test results in a screening woman and to assess the accuracy between cytology and Human papilloma virus testing to evaluate the feasibility of integrating the latter as a primary test in the national cervical cancer screening program. Methods: A prospective study for women attending to early detection cervical clinic, during the period from May 2019 to May 2020. Patients who were sexually active were included in the study. Samples for conventional cytology and HPV by using real-time polymerase chain reaction technique for high risk types were taken concurrently. The prevalence of positive screening results and the difference in accuracy between two testing were estimated by McNemar’s χ2 test. Result: A total of 388 women were included in the study. The prevalence of positive test for hr-HPV was 2.1%(8) while the prevalence of abnormal cytology test was 19.1%(74), Concerning discordant pairs, 0.8%(3) of women had normal cytology with a positive hr-HPV test result and 17.8%(69) of women had abnormal cytology with a negative  hr-HPV test result. A total of 311 (80.1%) women had normal cytology and negative hr-HPV test results. The proportion of women with abnormal cytology and positive hr-HPV test results was 1.3% (5 women). the difference in accuracy between the two results was statistically significant (<0.0001). The prevalence of positive hr-HPV test decreased with increasing age, whereas the prevalence of abnormal cytology showed a bimodal age pattern. Conclusion: The prevalence of abnormal cytology was high to that of hr-HPV testing, which could not allow for the implementation of hr-HPV as a primary test in the national screening program in Iraq.

Author(s):  
Abha Goyal ◽  
Diane D. Davey ◽  
Rhona J. Souers ◽  
Sana O. Tabbara ◽  
Kelly Goodrich ◽  
...  

Context.— The yield of the prospective rescreening process for “negative for intraepithelial lesion or malignancy” (NILM) Papanicolaou (Pap) tests is higher with the inclusion of a greater proportion of high-risk cases. One of the suggested criteria for classifying a Pap test finding as high-risk is recent or concurrent high-risk human papillomavirus (HPV) positivity. Objective.— To evaluate how the results of HPV testing have been incorporated in the prospective rescreening of NILM Pap tests across a wide range of laboratories. Design.— A questionnaire survey was sent to laboratories participating in the 2019 College of American Pathologists (CAP) Gynecologic Cytology (PAP Education) Program. Results.— Of the 1507 participating laboratories, 667 (44%) responded to the survey. Most laboratories (59.4%; 396 of 667) had not incorporated HPV test/genotyping results to select NILM Pap tests for rescreening. Amongst the remaining laboratories, for NILM HPV-positive Pap test results, 112 (16.8%) had a policy to rescreen by a cytotechnologist only, 51 (7.6%) by a pathologist only, and 86 (12.9%) by both. Of 264 laboratories, 181 (68.6%) reported the cytology upon availability of the HPV test result and completion of the secondary review. Of 661 laboratories, 145 (21.9%) included consensus-type recommendations in the cytology report for such Pap tests. Conclusions.— This CAP survey provides significant information regarding the current trends in the use of HPV test results in prospective rescreening of NILM Pap tests. Future studies on quality improvement can further assist in the standardization of this process across different laboratories.


2015 ◽  
Vol 9 (1) ◽  
pp. 38-45
Author(s):  
Ashna J. Faik Faik ◽  
Mudhafar Q. Saber Saber ◽  
Wisam J. Mohammed Mohammed ◽  
Bashar Z. Ibraheem Ibraheem ◽  
Kawther R. Lateef Lateef ◽  
...  

Human papilloma virus (HPV) infection is a causative factor for cervical cancer. Early detectionrisk HPV types might help to identify women at high risk of cervical cancer. The aim of of highHPV infection in population of rgir hgih determine the occurrence of the present study was toIraqi women in Baghdad by using Multiplex PCR determine the percentage and genotyping ofHuman Papilloma Virus and to put the best prevention and control program in Iraqi women.Study started at January 2009 to March 2010, cervical samples were collected from 856 womenaged 16–70. HPV DNA amplification was performed using HPV High Risk Typing PCR Kit testfor qualitative detection and genotyping of HPV types 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 66 inHPV was detected in 106 ( 12,38% ) of the study population, with a range of the cervical swabs.16-70 years age groups. Results showed that the overall HPV prevalence twelve genotypes wereidentified, including HPV-33 (18.60%), HPV-35 (18.60%), HPV-56 (18.60%) ,HPV-39(10.85%),HPV-52 (10.08%), HPV-18 (7.75%), HPV-16 (4.65%), HPV-59 (4.65%), HPV-58(2.32%), HPV-31(1.55%), HPV-45(1.55% ) and HPV-66( 0.77%). Of 856, 218 women was also tested by pap smearith normal cytology was 198 ( 90.83%), 24(12.12%) of them were HPV positive, those with w,abnormal cytology was 20 (9.17 %), 5( 25%)of them was HPV positive. In this study unlike otherepidemiological studies, HPV33,35,56 was the most frequent type (55.8%) in Baghdad, followedby HPV39, HPV52, HPV18, HPV16.


2015 ◽  
Vol 4 (5) ◽  
pp. 261-266 ◽  
Author(s):  
Anna Woodard ◽  
R. Marshall Austin ◽  
Zaibo Li ◽  
Joseph Beere ◽  
Chengquan Zhao
Keyword(s):  
Hpv 16 ◽  
Hpv Test ◽  

PEDIATRICS ◽  
1984 ◽  
Vol 73 (2) ◽  
pp. 183-187
Author(s):  
James R. Sorenson ◽  
Harvey L. Levy ◽  
Thomas W. Mangione ◽  
Stephen J. Sepe

Forty-five percent of the parents of 60 infants being retested in a newborn screening program for metabolic disorders understood that their infant was undergoing retesting because the first test result was abnormal. Fifty-five percent had incorrect or incomplete information, believing that retesting was routine, or that mistakes had been made in the original testing procedure, or they report being told nothing specific about the testing. Parents who were aware that the initial test was abnormal were no more anxious or depressed while waiting for the repeat test results than other parents. At a second interview after learning the normal results of the repeat test, both those parents informed of the initial abnormal result as well as those not informed were less anxious and depressed. However, 36% of the parents of these normal infants reported concern about the health of their infant because of the repeat testing. This concern was not related to a parent's knowledge that the initial test result was abnormal, but was greater in parents reporting that they had not received sufficient information about the screening/testing process and its significance for the health of their infant.


2020 ◽  
Vol 58 (6) ◽  
Author(s):  
Antonios Kritikos ◽  
Julien Poissy ◽  
Antony Croxatto ◽  
Pierre-Yves Bochud ◽  
Jean-Luc Pagani ◽  
...  

ABSTRACT The 1,3-beta-d-glucan (BDG) test is used for the diagnosis of invasive candidiasis (IC) in intensive care units (ICUs). However, its utility for patient management is unclear. This study assessed the impact of BDG test results on therapeutic decisions. This was a single-center observational study conducted in an ICU over two 6-month periods. All BDG test requests for the diagnosis of IC were analyzed. Before the second period, the ICU physicians received a pocket card instruction (algorithm) for targeted BDG testing in high-risk patients. The performance of the BDG test for IC diagnosis was assessed, as well as its impact on antifungal (AF) prescription. Overall, 72 patients had ≥1 BDG test, and 14 (19%) patients had an IC diagnosis. The BDG test results influenced therapeutic decisions in 41 (57%) cases. The impact of the BDG test was positive in 30 (73%) of them, as follows: AF abstention/interruption following a negative BDG result (n = 27), and AF initiation/continuation triggered by a positive BDG test result and subsequently confirmed IC (n = 3). In 10 (24%) cases, a positive BDG test result resulted in AF initiation/continuation with no further evidence of IC. A negative BDG result and AF abstention with subsequent IC diagnosis were observed in one case. The positive predictive value (PPV) of BDG was improved if testing was restricted to the algorithm’s indications (80% versus 36%, respectively). However, adherence to the algorithm was low (26%), and no benefit of the intervention was observed. The BDG result had an impact on therapeutic decisions in more than half of the cases, which consisted mainly of safe AF interruption/abstention. Targeted BDG testing in high-risk patients improves PPV but is difficult to achieve in ICU.


2020 ◽  
Vol 96 (3) ◽  
pp. 166-172 ◽  
Author(s):  
Rachael Helen Dodd ◽  
Olivia Mac ◽  
Julia M L Brotherton ◽  
Erin Cvejic ◽  
Kirsten J McCaffery

ObjectiveFrom December 2017, the Australian National Cervical Screening Program commenced 5 yearly primary human papillomavirus (HPV) screening; one of the first high-income countries to implement primary HPV screening. This study aimed to examine the psychosocial impact of self-reporting testing HPV positive in a sample of women screened since the renewal of the programme.MethodsWomen in Australia aged 25–74 years who reported participating in cervical screening since December 2017 were recruited through an online market research company to complete a cross-sectional survey. The primary outcomes were anxiety and general distress.Results1004 women completed the online survey; 80.9% reported testing HPV negative (HPV−), 6.5% reported testing HPV positive (HPV+) and 12.9% did not know/remember their test result. Women who reported testing HPV+ had significantly poorer psychological outcomes on a range of measures. Those who reported testing HPV+ had higher anxiety scores (53.03 vs 43.58 out of 80, p<0.001), showed more general distress (3.94 vs 2.52 out of 12, p=0.004), concern about their test result (5.02 vs 2.37, p<0.001), expressed greater distress about their test result (7.06 vs 4.74, p<0.001) and cancer worry (quite or very worried 35.4% vs 11.6%, p<0.001) than women who reported testing HPV−. Concern regarding test results was also significantly higher in women who did not know/remember their test result (3.20 vs 2.37, p<0.001) compared with women who reported testing HPV−. Women who reported testing HPV+ had greater knowledge of HPV (9.25 vs 6.62, p<0.001) and HPV testing (2.44 vs 1.30, p<0.001) than women who reported testing HPV−.ConclusionsReceipt of an HPV+ test result was associated with high levels of anxiety and distress, which reached clinical significance. Further work is needed to understand whether distress and concern could be reduced by ensuring all women receive high-quality standardised information with their results or by other interventions.


2013 ◽  
Vol 58 (1) ◽  
pp. 161-167 ◽  
Author(s):  
Arundhati Rao ◽  
Maria Teresa Sandri ◽  
Mario Sideri ◽  
Stephen Young ◽  
Abha Sharma ◽  
...  

2021 ◽  
Author(s):  
Daisuke Shiojiri ◽  
Daisuke Mizushima ◽  
Misao Takano ◽  
Koji Watanabe ◽  
Naokatsu Ando ◽  
...  

Abstract Background Anorectal high-risk human papillomavirus (hr-HPV) infection is associated with anal malignancies. However, the epidemiological data is quite limited in Japan. Methods Anorectal swab was obtained from HIV-infected and –uninfected men who have sex with men (MSM). Only high-risk HPV genotypes were examined by the Hybrid Capture-based methodology. Anal cytology was determined by the modification of the Bethesda System classification. Results In total, 644 participants were included. No participant had history of HPV vaccination at inclusion. The overall prevalence of hr-HPV was 58.5% (95% confidence interval: 54.7-62.3). The most frequently detected hr-HPV genotypes in order were HPV-52, -16, and -58. Among the HPV infected subjects, 82.8% (312/377) were infected with at least one of the 9 valent vaccine covered genotypes. Incidence of abnormal cytology was positively correlated with the number of HPV genotypes infected rather than the difference in genotypes. Multivariate analysis identified the number of detected hr-HPV genotypes as well as HIV-infection were the independent risk factors for pre-cancer. Conclusion Nine valent vaccine preventable HPVs are currently prevalent among MSM in Japan. Also, increased numbers of hr-HPV genotypes were strongly associated with anorectal pre-cancer. Universal HPV vaccination should be considered for Japanese MSM.


2019 ◽  
pp. 34-38
Author(s):  
N. M. Nazarova ◽  
K. I. Gusakov ◽  
E. G. Sycheva

If abnormal cytology test results are identified in the users of hormonal methods of contraception, including a vaginal ring, they should adhere to diagnostic algorithms aimed at identifying and treating HPV-associated cervical diseases. NovaRing vaginal ring is an effective, reliable and safe method of hormonal contraception, including for women who have previously undergone surgical treatment of HSIL.


2014 ◽  
Vol 66 (1) ◽  
pp. 51-56 ◽  
Author(s):  
G. Kovacevic ◽  
V. Milosevic ◽  
I. Hrnjakovic-Cvjetkovic ◽  
V. Petrovic ◽  
S. Stefan-Mikic ◽  
...  

HPV infection is considered to be the most important etiologic factor in cervical cancer development. In this retrospective study, which included the period from 2000 to 2012, the results of two molecular techniques used in the detection of HPV infection among women of the South Backa District were analyzed. By using the technique of in situ hybridization and the rPCR method, the proportion of high-risk HPV among women with normal cytology was determined to be 19.8% and 32.7%, respectively, and among women with abnormal cytology 43.1% and 61%, respectively. Among the analyzed women, HPV type 16 was the most prevalent, followed by HPV types 31, 51 and 18. Application of molecular HPV diagnosis is valuable because it increases the sensitivity of the screening test, so that the application of both tests to detect cervical cancer is a true prevention of malignancy.


Sign in / Sign up

Export Citation Format

Share Document